RxDoctor Payments Data

Shannon Martin

Family · Cumberland, MDNPI 1962001818

Payments from drug & device makers

$2,187in general payments, 2019–2025

Across 107 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$992
  • UCB, Inc.$438
  • Lilly USA, LLC$342
  • AstraZeneca$286
  • Biogen$39
  • Amgen$39
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$1,98791%
  • Education$2009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)57$992
UCB, Inc.18$438
Lilly USA, LLC17$342
AstraZeneca(2 entities)7$286
Biogen2$39
Amgen3$39
Teva Pharmaceuticals USA, Inc.1$20
Gilead1$17
Biohaven Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,187 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$150,729
Medicare patients
547
Services billed
3,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod13$176,434
UbrelvyUbrogepant68$94,453
AustedoDeutetrabenazine11$78,302
FingolimodFingolimod Hcl11$72,839
Dimethyl Fumarate11$54,029
Nurtec OdtRimegepant Sulfate22$28,838
Emgality PenGalcanezumab-Gnlm27$22,195
QuliptaAtogepant12$16,568
BriviactBrivaracetam11$15,905
Aimovig AutoinjectorErenumab-Aooe21$15,239
Memantine Hcl104$7,253
Levetiracetam236$6,809
Gabapentin425$6,006
VyvanseLisdexamfetamine Dimesylate13$4,962
Carbamazepine ErCarbamazepine30$4,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$992$111,02180 claims
Teva Pharmaceuticals USA, Inc.Austedo$20$78,30211 claims
UCB, Inc.Briviact$438$15,90511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →